Drugs / Anti-NY ESO-1 mTCR PBL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01967823 | Oct 2013 → Apr 2020 | breast cancer, hepatocellular carcinoma, melanoma, meningioma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-NY ESO-1 mTCR PBL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01967823 ↗ |
| Modality | Cell therapy | “genetically modifying them, and then giving the cells back to the patient” NCT01967823 ↗ |
| Route | Intravenous | “Cells will be infused intravenously (IV)” NCT01967823 ↗ |